Aiforia vs Ibex Medical Analytics
Ibex Prostate Detect is a 510(k) cleared prostate reader, K241232 from January 2025. Aiforia has no FDA clearance, and its prostate suite is research use outside the EU and EEA, which settles the choice for US labs. In Europe both are options. Aiforia reported IVDR certification in February 2025, offers a CE-IVD prostate biopsy suite and clinical suite viewer, and lets a lab build its own models in Aiforia Create. It publishes ISO 27001 and SOC 2 Type II, which Ibex does not state. Ibex lists CE marks on several solutions, with prostate under IVDR.
A Nordic hospital lab that must connect a prostate reader to existing scanners and an LIS gets a stated open API from Ibex, while Aiforia names no scanner or LIS, so Aiforia is the weaker connection. For a lab signing a long contract, Aiforia's FY2025 revenue near USD 4.0M (PitchBook, converted) and a EUR 20M EIB debt facility from July 2026 (Dealroom) are the scale facts that count.
Pathology · Reviewed November 1, 2026
Aiforia
by Aiforia Technologies
Pathology image analysis AI: CE-IVD prostate cancer biopsy suite and clinical suite viewer, plus research tools. No FDA clearance.
Ibex Medical Analytics
by Ibex
AI pathology software for prostate, breast and gastric cancer. One US FDA 510(k) clearance, for prostate.
When to pick each one
Aiforia
- CE-IVD prostate suite, IVDR reported February 2025
- SOC 2 Type II and ISO 27001
- Aiforia Create for building own models
Ibex Medical Analytics
- Prostate 510(k) K241232, January 2025
- Open API to scanners, image management and LIS
Score
Each row shows points earned of points available under the published rubric.
Aiforia
31of 100
Ibex Medical Analytics
33of 100
| Dimension | Aiforia | Ibex Medical Analytics | Difference |
|---|---|---|---|
| FDA clearance | 0 / 18 | 18 / 18 | -18 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 14.7 / 21 | 0 / 21 | +14.7 |
| RCT / meta-analysis / systematic review | 3.9 / 7.8 | 0 / 7.8 | +3.9 |
| Funding & adoption signal | 6 / 12 | 8.4 / 12 | -2.4 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 0 / 6 | 0 / 6 | 0 |
Scroll horizontally to see every column.
Pricing
Aiforia
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. The pricing page returns a 404. |
Ibex Medical Analytics
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Sold to laboratories and health systems on enterprise contracts. |
Evidence
Aiforia
FDA decisions
No FDA decision cited in our research as of October 20, 2026.
Peer-reviewed
3 PubMed records name Aiforia.
- A deep-learning algorithm (AIFORIA) for classification of hematopoietic cells in bone marrow aspirate smears based on nine cell classes-a feasible approach for routine screening? (opens in new tab)
- Comparing non-machine learning vs. machine learning methods for Ki67 scoring in gastrointestinal neuroendocrine tumors. (opens in new tab)
- A machine learning model of lamina propria fibrosis in eosinophilic esophagitis for prediction of fibrostenotic disease. (opens in new tab)
Ibex Medical Analytics
FDA decisions
K241232 (opens in new tab)510(k)2025-01-24
Galen Second Read (Ibex Prostate Detect)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Aiforia | Ibex Medical Analytics |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | n/a | n/a |
| HQ | FI | IL |
Scroll horizontally to see both columns.
Common questions
Open the full pathology comparison
Digital pathology workflows with FDA-cleared cancer detection (prostate, breast, colon), IHC scoring (HER2, Ki67), and AI-powered image management. Tempus, PathAI, Proscia dominate.